These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 11737356)

  • 1. Economic impact of HIV protease inhibitor therapy in the global use of health-care resources.
    Velasco M; Gómez A; Fernández C; Pérez-Cecilia E; Téllez MJ; Roca V; Fernández-Cruz A
    HIV Med; 2000 Oct; 1(4):246-51. PubMed ID: 11737356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm(3)).
    Floridia M; Massella M; Bucciardini R; Perucci CA; Rossi L; Tomino C; Fragola V; Ricciardulli D; Galluzzo CM; Giannini G; Pirillo MF; Andreotti M; Mirra M; Vella S
    HIV Clin Trials; 2000; 1(2):9-16. PubMed ID: 11590493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the use of health resources by Spanish and immigrant HIV-infected patients.
    Velasco M; Castilla V; Guijarro C; Moreno L; Barba R; Losa JE
    Enferm Infecc Microbiol Clin; 2012 Oct; 30(8):458-62. PubMed ID: 22377495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of HIV medical care in the era of highly active antiretroviral therapy.
    Gebo KA; Chaisson RE; Folkemer JG; Bartlett JG; Moore RD
    AIDS; 1999 May; 13(8):963-9. PubMed ID: 10371178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing cost of English HIV service provision 1996-1997. NPMS Steering Group. National Prospective Monitoring System.
    Int J STD AIDS; 1999 Jun; 10(6):357-62. PubMed ID: 10414877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting HIV care costs using CD4 counts from clinical trials.
    Hill A; Gebo K
    Am J Manag Care; 2007 Sep; 13(9):524-8. PubMed ID: 17803366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of delaying or preventing AIDS in persons with HIV.
    Pinkerton SD; Holtgrave DR
    Am J Manag Care; 1999 Mar; 5(3):289-98. PubMed ID: 10351025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA.
    Mouton Y; Alfandari S; Valette M; Cartier F; Dellamonica P; Humbert G; Lang JM; Massip P; Mechali D; Leclercq P; Modai J; Portier H
    AIDS; 1997 Oct; 11(12):F101-5. PubMed ID: 9342061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
    Simpson KN; Jones WJ; Rajagopalan R; Dietz B
    Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in hospitalization costs, morbidity, disability, and mortality in patients with aids treated with protease inhibitors.
    Lavalle C; Aguilar JC; Peña F; Estrada-Aguilar JL; Aviña-Zubieta JA; Madrazo M
    Arch Med Res; 2000; 31(5):515-9. PubMed ID: 11179588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health technology assessment in the HIV setting: the case of monotherapy.
    Restelli U; Croce D; Porazzi E; Scolari F; Bonfanti M; Galli M; Gianotti N; Rizzardini G; Garagiola E; Vanzago A; Foglia E
    New Microbiol; 2014 Jul; 37(3):247-61. PubMed ID: 25180841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study.
    Richter A; Pladevall M; Manjunath R; Lafata JE; Xi H; Simpkins J; Brar I; Markowitz N; Iloeje UH; Irish W
    HIV Med; 2005 Mar; 6(2):79-90. PubMed ID: 15807713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.
    Cook J; Dasbach E; Coplan P; Markson L; Yin D; Meibohm A; Nguyen BY; Chodakewitz J; Mellors J
    AIDS Res Hum Retroviruses; 1999 Apr; 15(6):499-508. PubMed ID: 10221527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain].
    Smets E; Brogan AJ; Hill A; Adriaenssen I; Sawyer AW; Domingo-Pedrol P; Gostkorzewicz J; Ledesma F
    Enferm Infecc Microbiol Clin; 2013; 31(7):430-6. PubMed ID: 23260386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients].
    Llibre-Codina JM; Casado-Gómez MA; Sánchez-de la Rosa R; Pérez-Elías MJ; Santos-González J; Miralles-Alvarez C; Martínez-Chamorro E; Domingo-Pedrol P; Alvarez-García ML; Moreno-Guillén S
    Enferm Infecc Microbiol Clin; 2007 Feb; 25(2):98-107. PubMed ID: 17288907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.
    Möller J; Desai K; Simpson K; Baran RW; Van de Steen O; Dietz B; Gooch K
    J Med Econ; 2014 Apr; 17(4):250-8. PubMed ID: 24351091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Health care resources utilization in HIV-infected patients: creation of a data base and cost results].
    Mompó C; Abbas I; Santín M; Rovira J; Antón F; Tomás C; Antoñanzas F
    Gac Sanit; 2000; 14(1):39-47. PubMed ID: 10757861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.
    Walensky RP; Weinstein MC; Yazdanpanah Y; Losina E; Mercincavage LM; Touré S; Divi N; Anglaret X; Goldie SJ; Freedberg KA;
    AIDS; 2007 May; 21(8):973-82. PubMed ID: 17457091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy.
    Anis AH; Hogg RS; Wang XH; Yip B; Palepu A; Montaner JS; O'Shaughnessy MV; Schechter MT
    Pharmacoeconomics; 1998 Jun; 13(6):697-705. PubMed ID: 10179705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.